Biology subjects

Rockman, H. A.

Publications and source records attributed to Rockman, H. A..

4 recordsLinked to original sources

bioRxiv2026

Conformational Basis of Functionally Selective Allosteric Modulation of the Angiotensin II type 1 Receptor by Small Molecules

Blockade of signaling through the angiotensin II type 1 receptor (AT1R), a prototypical G protein-coupled receptor (GPCR), by angiotensin receptor blockers (ARBs) is a major therapeutic approach to treating a wide variety of cardiovascular and renal diseases1. Like most GPCRs, the AT1R signals through two transducers, G proteins and {beta}-arrestins2,3. Previous reports have described {beta}-arrestin-biased peptide orthosteric agonists for the AT1R with potential therapeutic advantages over currently available unbiased ARBs4-6. Here we report the DNA- encoded library screening-guided isolation and pharmacological characterization of the first small molecule AT1R allosteric ligands. We use cryo-electron microscopy, double electron- electron resonance spectroscopy, molecular dynamics simulations, and targeted mutagenesis to determine their binding sites, binding modes and conformational mechanisms driving their unique and divergent modulatory effects on G protein and {beta}-arrestin pathways. Our findings uncover new mechanisms for precisely controlling the dynamic behavior of the AT1R with implications for drug development targeting this pathophysiologically important receptor family.

biochemistry↗

bioRxiv2025

Adrenergic Hypersensitivity Drives Ventricular Arrhythmias Following Loss of Plexin-Mediated Cardiac Innervation

BackgroundVentricular arrhythmias (VAs) are a leading cause of death and arise from a combination of cardiac muscle injury and dysfunction of the intramyocardial sympathetic nerves that control cardiac electrophysiology. The adrenergic mechanisms by which intramyocardial nerves contribute to arrhythmogenesis are poorly understood. Semaphorin-plexin signaling pathways are responsible for developmental guidance of sympathetic nerves onto the heart and have previously been associated with VAs in humans. ObjectiveTo investigate adrenergic control of arrhythmogenesis, we probed the cardiac electrophysiology of a Plexin-A3/-A4 double knockout mouse with loss of cardiac adrenergic nerves. MethodsWe studied cardiac structure and function using tissue clearing, immunohistochemistry, and echocardiography. We utilized ECG and optical mapping of action potentials to evaluate electrophysiologic responses to pharmacologic beta ({beta})-adrenergic stimulation and blockade. We measured circulating catecholamines and quantified {beta}-adrenergic receptor ({beta}AR) density in cardiac membranes. Finally, we performed a phenome-wide association study utilizing data from the UK Biobank to search for associations between PLXNA4 and human arrhythmias. ResultsMice with loss of plexin-dependent cardiac innervation had structurally normal hearts but displayed spontaneous VAs driven by adrenergic hypersensitivity, as well as increased cardiac {beta}AR density. Several human PLXNA4 variants were associated with arrhythmia phenotypes. ConclusionThese data establish a model of VAs driven by enhanced adrenergic receptor signaling, in the absence of structural heart disease, which can be used to investigate adrenergic mechanisms of arrhythmogenesis and to identify novel antiarrhythmic targets.

physiology↗

bioRxiv2024

Small Molecule Modulators of Beta-arrestins

{beta}-arrestins are multifunctional regulators of G protein-coupled receptor (GPCR) signaling, orchestrating diverse downstream signaling events and physiological responses across the vast GPCR superfamily. While GPCR pharmacology has advanced to target orthosteric and allosteric sites, as well as G proteins and GRKs, comparable chemical tools to study {beta}-arrestins remain lacking. Here, we report the discovery of small-molecule inhibitors that selectively target {beta}-arrestins and delineate their mechanism of action through integrated pharmacological, biochemical, biophysical, and structural analyses. These inhibitors disrupt {beta}-arrestin-engagement with agonist-activated GPCRs, impairing desensitization, internalization, and {beta}-arrestin-dependent functions while sparing G protein-receptor coupling. Cryo-EM, MD simulations, and structure-guided mutagenesis reveal that one modulator, Cmpd-5, engages a cryptic pocket formed by the middle, C-, and lariat loops of {beta}-arrestin1--a critical receptor-binding interface--stabilizing a distinct conformation incompatible with GPCR engagement. Together, these findings provide a mechanistic framework for {beta}-arrestin modulation, introducing transducer-targeted strategies to fine-tune GPCR signaling and guide the development of pathway-specific therapeutics.

biochemistry↗

bioRxiv2022

Engineering and characterization of a long half-life relaxin receptor RXFP1 agonist

Relaxin-2 is a peptide hormone with important roles in human cardiovascular and reproductive biology. Its ability to activate cellular responses such as vasodilation, angiogenesis, and anti-inflammatory and anti-fibrotic effects have led to significant interest in using relaxin-2 as a therapeutic for heart failure and several fibrotic conditions. However, recombinant relaxin-2 has a very short serum half-life, limiting its clinical applications. Here we present protein engineering efforts targeting the relaxin-2 hormone in order to increase its serum half-life, while maintaining its ability to activate the G protein-coupled receptor RXFP1. To achieve this, we optimized a fusion between relaxin-2 and an antibody Fc fragment, generating a version of the hormone with a circulating half-life of up to five days in mice while retaining potent agonist activity at the RXFP1 receptor both in vitro and in vivo.

pharmacology and toxicology↗